Racepinephrine
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Racepinephrine
- Racepinephrine: From Vasoconstrictor/Adrenergic Therapy to Primary Hereditary Glaucoma
Racepinephrine: From Vasoconstrictor/Adrenergic Therapy to Primary Hereditary Glaucoma
One-Sentence Summary
Racepinephrine (DB11124) is the racemic form of epinephrine, an adrenergic agonist historically used for its vasoconstrictive and bronchodilatory properties (e.g., nebulized therapy for croup, topical hemostasis); it is not currently marketed in Taiwan, so no official Taiwan-approved indication is on file. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, with 0 clinical trials and 0 publications currently directly supporting this specific drug-disease pair — the signal rests entirely on adrenergic mechanism reasoning.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — drug is not marketed in Taiwan (0 licenses on file). Internationally, racemic epinephrine is used as an inhaled agent for croup/post-extubation stridor and as a topical vasoconstrictor/hemostatic. |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 (mechanism-based, no direct clinical trials or literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for racepinephrine is not available (DrugBank MOA field is a confirmed data gap). Based on known pharmacology, racepinephrine is the racemic mixture of epinephrine enantiomers and acts as a non-selective α/β adrenergic receptor agonist — the same pharmacological class as epinephrine itself.
Adrenergic agonists have a well-established, if largely historical, mechanistic link to intraocular pressure (IOP) control: α-receptor activation reduces aqueous humor production, while β-receptor activation promotes uveoscleral outflow. Topical epinephrine and its prodrug dipivefrin were once used clinically for open-angle glaucoma before being largely superseded by prostaglandin analogs and β-blockers. The TxGNN model’s top prediction — primary hereditary glaucoma, a rare genetic subtype of glaucoma — plausibly draws on this class-level mechanism. Notably, the model also ranked the related, more common phenotype open-angle glaucoma at rank 3 (score 99.56%) with an identical mechanistic rationale, reinforcing that the signal is being driven by the adrenergic-IOP pathway rather than a target unique to the hereditary subtype.
However, primary hereditary glaucoma involves distinct genetic and pathophysiological features (e.g., trabecular meshwork developmental abnormalities) that are not fully equivalent to the acquired/idiopathic open-angle glaucoma population in which adrenergic agents were historically studied. This is therefore a class-level mechanistic extrapolation rather than a disease-specific hypothesis, and no clinical or literature evidence currently exists for racepinephrine in either glaucoma phenotype.
Clinical Trial Evidence
Currently no related clinical trials registered.
(Note: rank-3 prediction “open-angle glaucoma” returned 6 clinical trials in the evidence pack, but all were graded “C” relevance — testing unrelated interventions such as suprachoroidal triamcinolone, bevacizumab, and glaucoma drainage devices, none involving racepinephrine or epinephrine-class agents. These do not constitute supporting evidence for this drug.)
Literature Evidence
Currently no related literature available.
US Market Information
Racepinephrine has no marketing authorization records in the Taiwan regulatory dataset (market_status: 未上市, 0 total licenses). No license table can be generated.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all currently unavailable in the evidence pack — flagged as Blocking data gap DG001, since TFDA label warnings/contraindications have not yet been retrieved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (primary hereditary glaucoma) is supported only by class-level adrenergic mechanism reasoning (L4), with zero clinical trials or literature directly evaluating racepinephrine in any glaucoma population. Combined with a Blocking safety data gap (no TFDA label, warnings, or contraindications available) and the fact that the drug is not currently marketed in Taiwan, there is insufficient evidence to advance past a research-question stage.
To proceed, the following is needed:
- Retrieve and parse the TFDA (or equivalent regulatory) package insert for warnings/contraindications (resolves DG001, currently blocking S1 safety screening)
- Confirm mechanism of action via DrugBank API (resolves DG002)
- Identify any epinephrine/adrenergic-class precedent literature or trials in open-angle or hereditary glaucoma to establish at least indirect class evidence
- Assess route compatibility — ophthalmic/topical delivery data for racepinephrine is not yet characterized (
route_compatibility.status: pending) - Given the drug’s adrenergic profile, prioritize cardiovascular safety review (arrhythmia, hypertension risk) before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.